S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
AssigneeErasmus University Medical Center Rotterdam
InventorRebekka Katharina Marita Schneider-Kramann
Life of this patent
Estimating the term…
Abstract
The current invention pertains to an inhibitor of a S100 protein, preferably an inhibitor of a S100A8 or S100A9 protein, for the prevention or treatment of a myeloproliferative neoplasm. In particular, the invention pertains to an inhibitor of a S100A8 or S100A9 protein, for the prevention or treatment of primary myelofibrosis. The invention further pertains to a diagnostic method for identifying a subject suffering from a myeloproliferative neoplasm, comprising a step of detecting the presence of a S100 protein, preferably S100A8 or S100A9, in a biological sample.
Claims13
A method of treatment, comprising administering an inhibitor of a S100 protein to a mammal that has myelofibrosis, wherein the inhibitor is a compound of formula (I)
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 is selected from the group consisting of H, methyl, ethyl, n-propyl, iso-propyl, methoxy, ethoxy, fluoro, chloro, bromo, trifluoromethyl, and trifluoromethoxy;
- R2 is C1-C4 alkyl;
- R3 is selected from the group consisting of methyl, methoxy, hydrogen, fluoro, chloro, bromo, trifluoromethyl, and trifluoromethoxy;
- and
- R4 is selected from the group consisting of hydrogen, fluoro and chloro, with the proviso that R4 is selected from fluoro and chloro only when R3 is selected from fluoro and chloro.
Dependencies are inferred from the claim text.